Werbung
Werbung

RNAC

RNAC logo

Cartesian Therapeutics, Inc. Common Stock

8.20
USD
Gesponsert
+0.07
+0.83%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Vor-Markt

8.38

+0.18
+2.20%

RNAC Ergebnisberichte

Positives Überraschungsverhältnis

RNAC übertreffen die 18 der letzten 38Schätzungen.

47%

Nächster Bericht

Datum des nächsten Berichts
11. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$96.56K
/
-$0.87
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-78.64%
/
-36.96%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+25.41%
/
+47.46%

Cartesian Therapeutics, Inc. Common Stock earnings per share and revenue

On 06. Nov. 2025, RNAC reported earnings of -1.38 USD per share (EPS) for Q3 25, missing the estimate of -0.86 USD, resulting in a -60.11% surprise. Revenue reached 452.00 tausend, compared to an expected 248.37 tausend, with a 81.99% difference. The market reacted with a -1.56% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.87 USD, with revenue projected to reach 96.56 tausend USD, implying an decrease of -36.96% EPS, and decrease of -78.64% in Revenue from the last quarter.
FAQ
For Q3 2025, Cartesian Therapeutics, Inc. Common Stock reported EPS of -$1.38, missing estimates by -60.11%, and revenue of $452.00K, 81.99% above expectations.
The stock price moved down -1.56%, changed from $7.67 before the earnings release to $7.55 the day after.
The next earning report is scheduled for 11. März 2026.
Based on 10 analysts, Cartesian Therapeutics, Inc. Common Stock is expected to report EPS of -$0.87 and revenue of $96.56K for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung